Axitinib Export Market Intelligence: India's 56 Suppliers Shipping to 28 Countries — TransData Nexus 2026

Q: Who are the top axitinib exporters from India?

The top axitinib exporters from India are: 1. SEATRACK INTERNATIONAL TRADEX PRIVATE LIMITED — $10.8K (11.6% market share); 2. GALAXY SUPER SPECIALITY — $9.4K (10.1% market share); 3. RMPL PHARMA LLP — $7.2K (7.7% market share); 4. MEDINEX HEALTHCARE — $6.4K (6.8% market share); 5. APRAZER HEALTHCARE PRIVATE LIMITED — $5.7K (6.1% market share). Together they account for 42.2% of India's total axitinib export value.

Q: What is the total export value of axitinib from India?

The total export value of axitinib from India is $93.6K USD, recorded across 209 shipment transactions from 56 active exporters to 28 destination countries. The average shipment value is $448.

Q: Which countries import axitinib from India?

India exports axitinib to 28 countries worldwide. The top importing countries are: IRAQ (31.4% share, $29.4K), MEXICO (10.7% share, $10.0K), BRAZIL (10.4% share, $9.7K), TURKEY (9.6% share, $8.9K), UNITED ARAB EMIRATES (9.1% share, $8.5K). These five markets account for 71.1% of total export value.

Q: What is the HS code for axitinib exports from India?

The primary HS code for axitinib exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of axitinib exports from India?

The average unit price for axitinib exports from India is $30.95 USD per unit, with prices ranging from $0.01 to $1217.92 depending on formulation, packaging, and order volume. The total market is valued at $93.6K across 209 shipments.

Q: Which ports handle axitinib exports from India?

The primary ports for axitinib exports from India are DELHI AIR CARGO ACC (INDEL4) (23.9% of shipments), SAHAR AIR CARGO ACC (INBOM4) (19.6% of shipments), SAHAR AIR (15.8% of shipments), DELHI AIR (14.8% of shipments), Bombay Air (4.8% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of axitinib?

India is one of the world's leading exporters of axitinib due to its large base of 56 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports axitinib to 28 countries, demonstrating 14% global market coverage.

Q: What certifications do Indian axitinib exporters need?

Indian axitinib exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import axitinib from India?

There are 77 registered buyers importing axitinib from India, spread across 28 countries. The repeat buyer rate is 39.0%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top axitinib supplier from India?

SEATRACK INTERNATIONAL TRADEX PRIVATE LIMITED is the leading axitinib exporter from India with a market share of 11.6% and total export value of $10.8K across 15 shipments. The top 5 suppliers together control 42.2% of total export value.

Suresh Sormare

Axitinib

India Pharmaceutical Trade Intelligence

$93.6K56 Suppliers28 CountriesHS 30049049

ExportsIndia → IRAQ31.4%India → MEXICO10.7%

ImportsGERMANY → India$2.9M UNITED STATES → India$342.9K

#1 Supplier: SEATRACK INTERNATIONAL #1 Buyer: ATLAS TRADING

Axitinib Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Axitinib to the World

Between 2022 and 2026, India exported $93.6K worth of axitinib across 209 verified shipments to 28 countries — covering 14% of world markets in the Advanced Oncology segment. The largest destination is IRAQ (31.4%). SEATRACK INTERNATIONAL TRADEX PRIVATE LIMITED leads with a 11.6% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Axitinib export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Axitinib export data snapshot — $93.6K · 56 exporters · 28 countriesTransData Nexus · Indian Customs Data

Top Axitinib Exporters from India

56 active exporters · Ranked by export value

View all 56 →

Top Axitinib Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	SEATRACK INTERNATIONAL TRADEX PRIVATE LIMITED	$10.8K	15	1	11.6%
2	GALAXY SUPER SPECIALITY

Top Countries Importing Axitinib from India

28 destination markets · Ranked by import value

All 28 countries →

Top Countries Importing Axitinib from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	IRAQ	$29.4K	31.4%
2	MEXICO	$10.0K	10.7%
3	BRAZIL	$9.7K	10.4%
4	TURKEY	$8.9K	9.6%
5	UNITED ARAB EMIRATES	$8.5K	9.1%
6	VENEZUELA	$5.2K	5.6%
7	MAURITIUS	$4.9K	5.2%
8	UGANDA	$2.2K	2.3%
9	LEBANON	$2.1K	2.2%
10	NIGERIA	$1.9K	2.0%

IRAQ is India's largest axitinib export destination, absorbing 31.4% of total exports worth $29.4K. The top 5 importing countries — IRAQ, MEXICO, BRAZIL, TURKEY, UNITED ARAB EMIRATES — together account for 71.1% of India's total axitinib export value. The remaining 23 destination countries collectively receive the other 28.9%, indicating a focused distribution strategy targeting key markets.

Who Supplies Axitinib to India?

6 origin countries · Total import value: $3.4M

India imports axitinib from 6 countries with a combined import value of $3.4M. The largest supplier is GERMANY ($2.9M, 13 shipments), followed by UNITED STATES and CANADA. All values are from Indian Customs (DGFT) import records.

Countries Supplying Axitinib to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	GERMANY	$2.9M	13	87.2%
2	UNITED STATES	$342.9K	10	10.2%
3	CANADA	$43.0K	5	1.3%
4	BRAZIL	$33.3K	5	1.0%
5	SPAIN	$12.5K	2	0.4%
6	GREECE	$352	2	0.0%

GERMANY is the largest supplier of axitinib to India, accounting for 87.2% of total import value. The top 5 origin countries — GERMANY, UNITED STATES, CANADA, BRAZIL, SPAIN — together supply 100.0% of India's axitinib imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Axitinib

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

Axitinib, marketed under the brand name Inlyta, received FDA approval in January 2012 for the treatment of advanced renal cell carcinoma. As of March 2026, the FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for generic versions of axitinib, indicating a competitive generic market. The regulatory pathway for axitinib in the U.S. involves submission of an ANDA demonstrating bioequivalence to the reference listed drug, Inlyta. Notably, there are no current FDA import alerts or restrictions specific to axitinib, facilitating its importation into the U.S. market.

Despite the presence of 56 active Indian exporters of axitinib, the U.S. does not feature among the top five destination countries for Indian exports of this drug. This suggests that while the U.S. market is open to axitinib imports, other markets may be more prominent destinations for Indian exporters.

2EU & UK Regulatory Framework

In February 2011, the European Medicines Agency (EMA) granted orphan designation to axitinib for the treatment of renal-cell carcinoma. However, this designation was later withdrawn. Axitinib is subject to the EU's Good Manufacturing Practice (GMP) requirements, ensuring that imported pharmaceuticals meet stringent quality standards. Similarly, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) mandates compliance with GMP for all medicinal products. Indian exporters must adhere to these regulations to access the EU and UK markets.

3WHO Essential Medicines & Global Standards

As of the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, axitinib is not included. This exclusion indicates that, while axitinib is recognized for its therapeutic value, it is not considered essential for meeting the priority health care needs of the population on a global scale. Consequently, axitinib is not part of the WHO Prequalification Programme, which focuses on medicines deemed essential. Regarding pharmacopoeia standards, axitinib is listed in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), and European Pharmacopoeia (EP), providing standardized quality benchmarks for its production and quality control.

4India Regulatory Classification

In India, axitinib is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for axitinib, allowing market-driven pricing. For export purposes, Indian pharmaceutical companies must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating the monitoring of pharmaceutical exports.

5Patent & Exclusivity Status

The primary patent for axitinib has expired, leading to increased generic competition. This expiration has enabled multiple manufacturers to produce and export generic versions of axitinib, contributing to the presence of 56 active Indian exporters and a total export value of $0.1 million USD.

6Recent Industry Developments

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines. The 24th edition, published in September 2025, did not include axitinib, reflecting ongoing evaluations of its global essentiality. (who.int)

In November 2025, the WHO launched a virtual cGMP Training Marathon to enhance manufacturing workforce skills across all regions, aiming to improve compliance with GMP standards among pharmaceutical manufacturers, including those producing axitinib. (who.int)

In December 2025, the WHO issued a Medical Product Alert regarding falsified versions of IBRANCE (palbociclib), highlighting the importance of vigilance against counterfeit oncology drugs, a concern relevant to axitinib manufacturers and exporters. (who.int)

In January 2026, the WHO published the 39th volume of WHO Drug Information, providing updates on pharmaceutical standards and regulations, which are pertinent to axitinib's manufacturing and export processes. (who.int)

In February 2026, the WHO released the report of the 25th Expert Committee on Selection and Use of Essential Medicines, offering insights into the selection criteria and considerations for essential medicines, indirectly impacting the market dynamics of drugs like axitinib. (who.int)

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Axitinib

Retail & reference prices across 9 markets vs. India FOB export price of $30.95/unit

Global Price Benchmark for Axitinib across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$26.59	USD	According to the FDA, Axitinib is approved for the treatment of advanced renal cell carcinoma.
United Kingdom	$3.25	GBP	As per the NHS Drug Tariff, Axitinib is listed for the treatment of advanced renal cell carcinoma.
Germany	$3.30	EUR	The European Medicines Agency (EMA) has authorized Axitinib for use in advanced renal cell carcinoma.
Australia	$2.80	AUD

Supply Chain Risk Assessment — Axitinib

API sourcing, concentration risk, storage requirements, and current alerts

MEDIUM RISK

1API Sourcing & Raw Material Dependency

Axitinib, a tyrosine kinase inhibitor used in cancer treatment, is primarily manufactured in India. The production of Active Pharmaceutical Ingredients (APIs) for such drugs often relies on Key Starting Materials (KSMs) sourced from China. This dependency exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and production disruptions in China.

Recent events have highlighted the vulnerabilities in this supply chain. For instance, in March 2026, the closure of the Strait of Hormuz due to regional conflicts led to significant disruptions in shipping routes, affecting the timely delivery of raw materials and APIs. Such incidents underscore the need for diversification in sourcing strategies to mitigate potential supply chain interruptions.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the top five exporters of Axitinib from India account for 42.2% of the total export value, with SEATRACK INTERNATIONAL TRADEX PRIVATE LIMITED leading at an 11.6% share. This concentration suggests a moderate risk of supply disruption if any of these key suppliers face operational challenges.

The Indian government's Production Linked Incentive (PLI) scheme, initiated in March 2020, aims to boost domestic manufacturing of pharmaceuticals and reduce reliance on imports. While this initiative has encouraged diversification, the current supplier concentration indicates that further efforts are needed to achieve a more balanced supply chain.

Access Complete Axitinib Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 209 transactions across 28 markets.

Request Demo View Pricing

Frequently Asked Questions — Axitinib Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top axitinib exporters from India?

The leading axitinib exporters from India are SEATRACK INTERNATIONAL TRADEX PRIVATE LIMITED, GALAXY SUPER SPECIALITY, RMPL PHARMA LLP, and 8 others. SEATRACK INTERNATIONAL TRADEX PRIVATE LIMITED leads with 11.6% market share ($10.8K). The top 5 suppliers together control 42.2% of total export value.

What is the total export value of axitinib from India?

The total export value of axitinib from India is $93.6K, recorded across 209 shipments from 56 active exporters to 28 countries. The average shipment value is $448.

Which countries import axitinib from India?

India exports axitinib to 28 countries. The top importing countries are IRAQ (31.4%), MEXICO (10.7%), BRAZIL (10.4%), TURKEY (9.6%), UNITED ARAB EMIRATES (9.1%), which together account for 71.1% of total export value.

What is the HS code for axitinib exports from India?

The primary HS code for axitinib exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Axitinib

Axitinib

Top Axitinib Exporters from India

Top Countries Importing Axitinib from India

Who Supplies Axitinib to India?

Quick Facts

Related Advanced Oncology

Related Analysis

Need Details?

Regulatory Landscape — Axitinib

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Axitinib

Supply Chain Risk Assessment — Axitinib

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Axitinib Trade Intelligence

Frequently Asked Questions — Axitinib Exports from India

Who are the top axitinib exporters from India?

What is the total export value of axitinib from India?

Which countries import axitinib from India?

What is the HS code for axitinib exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of axitinib exports from India?

Which ports handle axitinib exports from India?

Why is India a leading exporter of axitinib?

What certifications do Indian axitinib exporters need?

How many buyers import axitinib from India?

What is the market share of the top axitinib exporter from India?

Analysis Methodology